Skip to main content
PMC home page
Stem Cell Research & Therapy logoLink to Stem Cell Research & Therapy
. 2020 Sep 7;11:387. doi: 10.1186/s13287-020-01906-1

Regeneration of a full-thickness defect of rotator cuff tendon with freshly thawed umbilical cord-derived mesenchymal stem cells in a rat model

Ji-Hye Yea 1,2, Jin-Kyung Park 2, In Ja Kim 2, Gayoung Sym 2, Tae-Soo Bae 3, Chris Hyunchul Jo 1,2,✉
PMCID: PMC7487485  PMID: 32894193

Abstract

Background

It is difficult to immediately use mesenchymal stem cells (MSCs) for the patient with rotator cuff disease because isolation and culture time are required. Thus, the MSCs would be prepared in advanced in cryopreserved condition for an “off-the-shelf” usage in clinic. This study investigated the efficacy of freshly thawed MSCs on the regeneration of a full-thickness tendon defect (FTD) of rotator cuff tendon in a rat model.

Methods

We evaluated morphology, viability, and proliferation of cultured umbilical cord-derived MSCs (C-UC MSCs) and freshly thawed umbilical cord-derived MSCs (T-UC MSCs) at passage 10 in vitro. In animal experiments, we created a FTD in the supraspinatus of rats and injected the injured tendon with saline, cryopreserved agent (CPA; control), C-UC MSCs, and T-UC MSCs, respectively. Two and 4 weeks later, macroscopic, histological, biomechanical, and cell trafficking were evaluated. T test and ANOVA were used with SPSS. Differences with p < .05 were considered statistically significant.

Results

T-UC MSCs had fibroblast-like morphology and showed greater than 97% viability and stable proliferation comparable to the C-UC MSCs at passage 10. In animal experiments, compared with the control group, the macroscopic appearance of the T-UC MSCs was more recovered at 2 and 4 weeks such as inflammation, defect size, neighboring tendon, swelling/redness, the connecting surrounding tissue and slidability. Histologically, the nuclear aspect ratio, orientation angle of fibroblasts, collagen organization, and fiber coherence were improved by 33.33%, 42.75%, 1.86-fold, and 1.99-fold at 4 weeks, and GAG-rich area decreased by 88.13% and 94.70% at 2 and 4 weeks respectively. Further, the T-UC MSCs showed enhanced ultimate failure load by 1.55- and 1.25-fold compared with the control group at both 2 and 4 weeks. All the improved values of T-UC MSCs were comparable to those of C-UC MSCs. Moreover, T-UC MSCs remained 8.77% at 4 weeks after injury, and there was no significant difference between C-UC MSCs and T-UC MSCs.

Conclusions

The morphology, viability, and proliferation of T-UC MSCs were comparable to those of C-UC MSCs. Treatment with T-UC MSCs could induce tendon regeneration of FTD at the macroscopic, histological, and biomechanical levels comparable to treatment with C-UC MSCs.

Keywords: Rotator cuff, Tendon regeneration, Mesenchymal stem cells, Cryopreservation

Background

Rotator cuff disease is a major cause of shoulder pain, and approximately 300,000 operations are performed each year in the USA [1, 2]. After conservative treatments such as rest, non-steroidal anti-inflammatory drugs, physical therapy, and various kinds of injections [3], at least 45% patients suffer from persistent symptoms even after 12 months [4]. These symptoms are attributed to the low healing potential of the rotator cuff tendon due to the avascular and acellular structure, and the tenocytes no longer participate in the regeneration of tendon after injury [5]. Thus, spontaneous healing of tendon disease is a difficult proposition.

Recently, mesenchymal stem cells (MSCs) have emerged as a promising candidate for fundamental tissue regeneration of rotator cuff tendon [6]. Bone marrow-derived MSCs (BM MSCs) and adipose tissue-derived MSCs (AD MSCs) improve collagen organization and collagen fiber coherence and enhance the tensile strength of tendon in a rat model of rotator cuff injury [7, 8]. However, the use of these MSCs entails invasive harvesting techniques [9], low collection efficiency [10], decreased ability with age, and donor morbidities [11]. Especially, heterotopic bone formation induced by BM MSCs is a crucial risk factor limiting clinical application. Umbilical cord-derived MSCs (UC MSCs) represent an alternative cell source. UC MSCs isolated from the umbilical cord, which is a medical waste following delivery, could be obtained non-invasively and at relatively low cost [10]. It has higher proliferative and self-renewal potential than other adult MSCs [12]. In regenerative medicine, it is reported that UC MSCs can be used to recover tissue structure in a mouse model of ischemic injury [13] and a C57BL6 mouse model of wound injury [14]. Thus, UC MSCs could be used to potentially recover the tendon tissue of rotator cuff.

For clinical application, an “off-the-shelf” usage with allogeneic MSCs is more promising than usage after isolation and culture in each case, or usage with rescue culture for several days after thawing for allogeneic MSCs. However, MSCs might be subjected to substantial physiological changes such as cell growth, phenotype, differentiation, viability, and safety profile in vivo during the freshly thawing procedure [15, 16]. The results of applying freshly thawed MSCs to animal models vary with the study. The freshly thawed MSCs are impacted by factors associated with post-infusion biodistribution as they bind poorly with fibronectin, human endothelial cells, and cytoskeletal F-actin compared with cultured MSCs. Freshly thawed MSCs were undetectable in the lung tissues of C57BM/B6 mice whereas the cultured MSCs could be detected for up to 24 h [17]. In contrast, another study reported that the freshly thawed MSCs had a healing effect on allergic airway inflammation in a mouse model comparable to that of cultured MSCs [18]. These conflicting results suggest a potential risk associated with the clinical use of freshly thawed MSCs. However, the healing potential of MSCs is disease-specific and affected by factors such as tissue origin, donor variation, culture time, supplements, and other aspects associated with delivery [16]. Thus, the efficacy of specific cells under specific disease conditions remains to be investigated. Until now, although some studies investigated tissue healing using UC MSCs, the role of freshly thawed UC MSCs (T-UC MSCs) in tendon recovery for clinical use compared with continuously cultured UC MSCs (C-UC MSCs) has never been reported.

Therefore, this study investigated the efficacy of T-UC MSCs in a rat model of full-thickness tendon defect (FTD) of the supraspinatus tendon. We hypothesized that T-UC MSCs have comparable morphology, viability, and proliferation to those of C-UC MSCs. The T-UC MSCs could induce regeneration of tendon in terms of macroscopic, histological, and biomechanical characteristics comparable to C-UC MSCs.

Methods

UC MSCs isolation and culture

This study was approved by the Seoul Metropolitan Government Seoul National University Boramae Medical Center Institutional Review Board (IRB No. 16-2015-115). Informed consent was obtained from all patients before performing the study. Human umbilical cords were obtained from full-term birth via cesarean section. Isolated umbilical cords were washed 2 to 3 times with Dulbecco’s phosphate-buffered saline (DPBS; Welgene, Daegu, Korea) to remove blood products, and the length and weight were measured, followed by sectioning into minimal cube explants, each measuring 2–4 mm, using surgical scissors. The cube explants (1 g) were aligned at regular intervals in 15-cm culture dishes and allowed to firmly attach to the bottom of the dish for 60 min in a 5% CO2 incubator with humidified air at 37 °C. The culture medium consisting of low-glucose Dulbecco’s modified Eagle’s medium (LG-DMEM; Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone) and antibiotic-antimycotic solution (100 U/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B; Welgene) was gently poured into the dishes. The medium was replaced twice a week. Non-adherent cells were removed by changing the medium. When cells reached 80% confluency, they were detached by incubation for 3 min with trypsin-ethylendiaminetetracetic acid (EDTA) (0.05% trypsin, 0.53 mM EDTA; Welgene). The tissues were removed through a 100-μm cell strainer (SPL Life Sciences, Pocheon, Korea), and the cells were centrifuged at 500g for 5 min at 20 °C and then replated at a density of 3 × 103 cells/cm2. The culture medium was changed every 2–3 days and continuously cultivated. The C-UC MSCs were continuously cultured up to passage 10 before use in experiments and characterized morphologically, in addition to the determination of growth kinetics, CFU-F, flow-cytometric, and trilineage differentiation of cells as reported previously [19]. The T-UC MSCs were cryopreserved with a cryoprotective agent (CPA) (including 10% DMSO; ZENOAQ RESOURCE, Fukushima, Japan). Cryovials were stored at − 80 °C in a deep-freezer and transferred to − 196 °C liquid nitrogen tank for preservation up to 1 month. For use in experiments, T-UC MSCs were thawed immediately in the 37 °C water bath within 1 min. The T-UC MSCs were also used at the same passage as C-UC MSCs for each experiment.

Characterization of C- and T-UC MSCs

When C- and T-UC MSCs reached 80% confluence, cell morphologies were observed under a microscope (CKX53 Olympus culture microscope; Olympus, Tokyo, Japan).

Cell viability of C- and T-UC MSCs was determined by the trypan blue exclusion method and water-soluble tetrazolium salt (WST) assay. Cells were stained with trypan blue (0.4%) solution and the live and dead cells were counted using the hemocytometer. The percentages of cell viability of C- and T-UC MSCs were calculated using the following formula: total number of live cells/total number of cells × 100 (%). For WST assay, cell suspensions were plated at a density of 1 × 104 cells/well on a 96-well plate and incubated for 0, 2, 6, 24, and 48 h in the presence of 5% CO2 with humidified air at 37 °C. At the respective time points, 10 μL WST solution (WST assay kit; EZ3000, DAEILLAB SERVICE CO. Ltd.) was added to each well for 2 h in a 5% CO2 incubator with humidified air at 37 °C. After the 2 h incubation, optical density (OD) was measured at 450 nm using a microplate spectrophotometer (Power Wave XS; Bio-Tek Instruments, Winooski, VT, USA).

Proliferative capacities of C- and T-UC MSCs were evaluated by calculating the cumulative population-doubling level (CPDL) and population-doubling time (PDT). Cells were plated at a density of 3 × 103 cells/cm2 on a 6-well plate in triplicate. Cells were harvested every 4 days up to 20 days. PDT of cells was calculated using the following formula: PD = Log (Nf/Ni)/Log2, PDT = CT/PD, where CT denotes culture time, and Nf and Ni refer to the final and initial number of cell, respectively [20].

In vivo study design

Animal procedures were conducted in accordance with the protocol approved by the Seoul Metropolitan Government Seoul National University Boramae Medical Center Institutional Animal Care and Use Committee (IACUC_2020_0004). One hundred twenty adult male Sprague-Dawley rats (12 weeks old, 340~360 g) were divided into one of the four groups and treated accordingly: (1) saline group, (2) CPA group, (3) C-UC MSC group, and (4) T-UC MSC group. Rats from each group were sacrificed immediately after surgery, 2 and 4 weeks after surgery. The supraspinatus tendon (SST) was harvested and used for macroscopic and histological evaluation (n = 4), biomechanical evaluation (n = 8), and cell trafficking (n = 4). Workflow was schematized in an Additional file 1.

Surgical procedures

Anesthesia was induced using zoletil and rompun (30 mg/kg + 10 mg/kg). The left shoulder was operated in all cases. A 20cm skin incision was made directly over the anterolateral border of the acromion. After the SST was exposed by detaching trapezius and deltoid muscle from the acromion, a round FTD with a diameter of 2 mm in the middle of the SST was created 1 mm from the insertion using a Biopsy Punch (BP-20F, Kai Medical Europe GmbH, Bremen, Germany). This defect size was approximately 50% of the tendon width, correlating with a large but not a massive tear according to the method previously described [21]. Ten microliters of saline, CPA, C-UC MSCs (1 × 106 cells in saline), and T-UC MSCs (1 × 106 cells in CPA) were intratendinously injected adjacent to both sides of the defect in two divided doses using a 30-G needle. After injection, the deltoid and trapezius muscles were sutured with a 4–0 Vicryl suture (W9074, Ethicon, Cincinnati, OH, USA), and the skin was also sutured with a black silk (SK439, AILee, Busa, Korea). After surgery, animals were allowed free cage activity.

Macroscopic evaluation

At 2 and 4 weeks after injection, the rats were sacrificed in a carbon dioxide chamber. The SST of the rats was harvested along with the humerus head without removing the muscle. For macroscopic evaluation, we used a modified semi-quantitative system described by Stoll et al. [22] (see Additional file 2). The 12 parameters in the system were tendon rupture, inflammation, tendon surface, neighboring tendon, level of the defect, defect size, swelling/redness of tendon, connection surrounding tissue and slidability, tendon thickness, color of tendon, single strain of muscle, and transition of the construct to the surrounding healthy tissue. Each parameter varied from 0 or 1 except for swelling/redness score (0 to 2) and tendon thickness score (0 to 3). Therefore, the total macroscopic score varied between 0 (normal tendon) and 15 (most severe injury).

Histological evaluation

After the macroscopic evaluation, the harvested tissues were immediately fixed in 4% (w/v) paraformaldehyde (PFA; Merck, Darmstadt, Germany) for 24 h, followed by decalcification in 10% EDTA (Sigma-Aldrich, St Louis, MO, USA) for 2 days. After decalcification, the tissues were dehydrated through an increasing series of ethanol gradient, defatted in chloroform, and embedded in paraffin blocks. The tissue was carefully trimmed to the appropriate middle site of tendon and cut into 4-μm-thick serial sections.

A randomly selected slide was stained with hematoxylin and eosin (H&E) and analyzed by light microscopy (U-TVO 63XC; Olympus Corp., Tokyo, Japan). For the evaluation of tendinopathy, each slide was evaluated using the semi-quantitative grading scale as previously described [23]. The 7 parameters of the system include fiber structure, fiber arrangement, rounding of the nuclei, variations in cellularity, vascularity, stainability, and hyalinization. Each parameter in the grading scales varies from 0 to 3. The total degeneration score for a given slide varied between 0 (normal tendon) and 21 (most severely degenerated).

For the evaluation of inflammation, infiltration of inflammatory cells was evaluated using a 0–3 grading scale: 0 (normal), 1(slightly abnormal), 2 (moderately abnormal), and 3 (maximally abnormal) [24].

In normal tendon, the few fibroblasts with flattened nuclei are typically aligned parallel to the tensile axis. After injury, the morphometric changes of fibroblast nuclei were evaluated as previously described by Fernandez-Sarmiento using H&E stained slides [25]. Fibroblast density (number of nuclei per mm2), nuclear aspect ratio (the ratio of the minor diameter to the maximal diameter), and nuclear orientation angle (between the major axis of the nuclear angle and the axis of collagen fibers) were evaluated. Five regions of interest (ROI) were measured and the average was used finally.

We also evaluated the occurrence of heterotopic ossification when separated, clustered, and bar-shaped foci were found in the whole tendon structure [26].

Slides were also stained with picrosirius red (PSR) for analysis of collagen fiber organization and coherency using circularly polarized light microscopy at × 200 magnification. Collagen organization was measured as intense white areas of brightly diffracted light on gray scale (black, 0; white, 255) using ImageJ software with installed NII plugin (National Institutes of Health, MD, USA). Higher gray scale indicated more organized and mature collagen [27]. The coherence of the collagen fibers is a measure of the extent of fiber alignment in the major axis of alignment. The coherence was quantified using the Orientation J plug-in for ImageJ and then multiplied by 100 to obtain the final coherence value [7]. Five ROIs were measured and the mean value was used. Moreover, slides were stained with Masson’s trichrome to evaluate collagen deposit, and immunohistochemistry (IHC) was performed to assess type I collagen formation after injury, using rabbit anti-type 1 collagen (1:300 dilution, Abcam; ab34710). Detailed procedures are described in Additional file 3.

For evaluation of cartilage formation, slides stained with alcian blue were used and observed via light microscopy at × 40 magnification. The glycosaminoglycan (GAG)-rich area was measured using ImageJ [11, 28].

Biomechanical evaluation

For biomechanical testing, we harvested supraspinatus tendon with humerus head and carefully removed the muscles to leave only the tendon. The harvested tissues were wrapped in saline-soaked gauze and kept at − 80 °C. Before testing, the tissues were thawed with saline wet gauze at room temperature for 24 h, and the tissues were kept moist with saline during all tests. The distal part of the humerus bone was vertically embedded in an aluminum tube full of polymethylmethacrylate (PMMA) in the custom-designed lower jig of a testing system. The proximal end of the tendon was compressed with sandpaper, gauge, and rubber to prevent slippage and to reduce damage of specimens. The complex was clamped vertically in the custom-designed upper jig. Testing was performed with shoulders at 90° of abduction with a material testing system (H5K5, Tinus Olsen, England, UK) [29, 30]. All specimens were loaded to failure in tension at a constant rate of 0.1 mm/s. Slippage of the tendon was inspected visually. The cross-sectional area of supraspinatus tendon was measured at the center of defect region and was calculated with the formula area = abπ/4. From the load-displacement curve recorded during tests, the ultimate failure load, the stiffness, and ultimate stress were calculated [28, 31].

UC MSCs trafficking

UC MSCs were labeled with red fluorescent PKH26 (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer’s protocol [32]. Detailed procedures are described in Additional file 4. After labeling, the cells were counted by hemocytometer and were confirmed by fluorescence microscope (Leica DMI 4000B, Leica, Wetzlar, Germany). After injection, the tissues were harvested immediately after injection and at 2 and 4 weeks after injection and used for evaluation (see Additional file 4). Five fields were randomly selected in the slide and high-powered images (× 400) were obtained by fluorescence microscopy. The PKH26 positive cells coincident with 4′,6-diamidino-2-phenylindole (DAPI) were counted per area and the mean number was recorded by ImageJ [33].

Statistical analysis

All data are shown as mean ± standard deviation. A T test was used to determine significance between the means of two groups in vitro, and animal experimental data were analyzed with one-way analysis of variance (ANOVA) with post hoc analysis using Bonferroni multiple comparison test. All statistical analyses were performed with SPSS software version 23 (IBM). Differences of p < 0.05 were considered statistically significant.

Results

Characterization of C- and T-UC MSCs

Both C- and T-UC MSCs showed fibroblast-like morphology (Fig. 1a). Viabilities of C- and T-UC MSCs were 98.25 ± 0.50% and 97.25 ± 1.50%, respectively, in trypan blue assay (Fig. 1b). In WST results, the viabilities were 32.1 ± 7.95 in C-UC MSCs and 29.8 ± 4.76 in T-UC MSCs at 6 h and 93.6 ± 6.68 in C-UC MSCs and 93.1 ± 4.48 in T-UC MSCs at 48 h (Fig. 1c). There was no significant difference between C- and T-UC MSCs.

Fig. 1.

Fig. 1

Open in a new tab

Characterization of C- and T-UC MSCs at passage 10. a Fibroblast-like morphology of cells (magnification; × 100). b Viability evaluated by trypan blue exclusion. c Viability evaluated by water-soluble tetrazolium salt (WST) assay. d Calculation of cumulative population-doubling level (CPDL). e Population-doubling time (PDT). Bar charts represent mean ± standard deviation; statistically significant at p < 0.050

Results of the proliferative capacity showed that the values of CPDL in C- and T-UC MSCs were 12.1 ± 1.9 and 12.0 ± 1.6, respectively, by day 20 (Fig. 1d). The mean values of PDT in C- and T-UC MSCs were 32.36 ± 1.86 h and 33.36 ± 1.58 h, respectively (Fig. 1e). No significant difference in proliferative capacity was detected between C- and T-UC MSCs.

Macroscopic evaluation

The total macroscopic score was significantly lower in the T-UC MSCs (8.75 ± 1.50) than in the CPA group (11.50 ± 1.29) (p = 0.044) at 2 weeks. Especially, the scores of neighboring tendon and the defect level were at least 0.5 points less in the T-UC MSCs than in the CPA group. No significant difference was found between C-UC MSCs (7.25 ± 0.96) and T-UC MSCs at 2 weeks. At 4 weeks, the total macroscopic score was significantly lower in the T-UC MSCs (4.75 ± 0.96) than in the CPA group (9.50 ± 1.91) (p = 0.001). The scores of inflammation, surface, defect size, neighboring tendon, defect level, swelling/redness, and the connecting surrounding tissue and slidability were at least 0.5 points lower in the T-UC MSCs than in the CPA group. There was no significant difference between the C-UC MSCs (3.50 ± 1.00) and the T-UC MSCs at 4 weeks (Fig. 2a, b).

Fig. 2.

Fig. 2

Open in a new tab

Macroscopic evaluation of regenerated tendons at 2 and 4 weeks after injection with saline, CPA, and C- and T-UC MSCs. a Macroscopic appearance of the supraspinatus tendon (left side: shape of a supraspinatus tendon immediately after detachment; right side: shape of the tendon without the loose connective tissue surrounding the defect site to observe the original defect). b The total macroscopic score. Bar charts represent mean ± standard deviation; statistically significant at p < 0.050

Histological evaluation

The total degeneration score showed no significant difference between T-UC MSCs and CPA groups at 2 weeks. After 4 weeks, the total degeneration score was significantly reduced in the T-UC MSCs group, 7.00 ± 2.16, compared with the CPA group, 17.25 ± 0.96 (All p < 0.001). The scores of fiber structure, fiber arrangement, rounding of nuclei, variations in cellularity, decreased stainability, and hyalinization were significantly lower in the T-UC MSCs groups than in the CPA groups. There was no significant difference in total degeneration score between C-UC MSCs (7.00 ± 1.41) and T-UC MSCs at 4 weeks. In vascularity, there were no significant differences among groups (Fig. 3a, b).

Fig. 3.

Fig. 3

Open in a new tab

Histological evaluation of regenerated tendon at 2 and 4 weeks after injection with saline, CPA, and C- and T-UC MSCs. a H&E staining of tendon (magnification; × 100). b The total degeneration score and detailed parameters. c Inflammation at the tendon defect. d Density, nuclear aspect ratio, and nuclear orientation angle of fibroblasts in the tendon. Bar charts represent mean ± standard deviation; statistically significant at p < 0.050

There was no significant immune response in the MSCs, and the inflammation scores were reduced in the C- and T-UC MSCs groups compared to the saline and CPA groups at 4 weeks, but there were no significant differences among groups at both 2 and 4 weeks (Fig. 3a, c).

At 2 weeks, the values of fibroblast density, nuclear aspect ratio, and nuclear orientation angle were not significantly different between T-UC MSCs and CPA groups. After 4 weeks, the fibroblast density was lower in T-UC MSCs (1308.32 ± 164.69 cells/mm2) than in the CPA group (1820.98 ± 117.20 cells/mm2) (p = 0.009), but there was no significant difference. The nuclear aspect ratio was significantly decreased in T-UC MSCs (0.26 ± 0.04) compared with the CPA group (0.39 ± 0.03) (p = 0.003). There was no significant difference between the C-UC MSCs (0.23 ± 0.03) and T-UC MSCs group at 4 weeks. The nuclear orientation angle was also lower in the T-UC MSCs (11.49 ± 3.15) than in the CPA group (20.07 ± 3.15) (p = 0.032). There was no significant difference between C-UC MSCs (7.59 ± 2.07) and T-UC MSCs at 4 weeks (Fig. 3a, d). Heterotopic ossification was not observed in any group at any time point (Fig. 3a).

The scores of collagen organization and collagen fiber coherence were not significantly different between T-UC MSCs and CPA groups at 2 weeks. After 4 weeks, collagen organization increased significantly in the T-UC MSC group (106.83 ± 13.46) compared with the CPA group (57.46 ± 16.94) (p = 0.002). There was no significant difference between C-UC MSCs (101.78 ± 13.89) and T-UC MSC groups at 4 weeks (Fig. 4a, d). The collagen fiber coherence was also higher in the T-UC MSC groups (39.94 ± 9.95) than in the control groups (20.07 ± 5.99) (p = 0.008). No significant differences were found between C-UC MSCs (42.95 ± 13.89) and T-UC MSCs at 4 weeks (Fig. 4a, e).

Fig. 4.

Fig. 4

Open in a new tab

Quantification of collagen matrix changes in regenerated tendon at 2 and 4 weeks after injection with saline, CPA, and C- and T- UC MSCs. a PSR staining of the tendon (magnification; × 200). b MT staining of the tendon (magnification; × 200). c IHC for type I collagen of the tendon (magnification; × 200). d Collagen organization in the tendon. e Collagen fiber coherence of the tendon. Bar charts represent mean ± standard deviation; statistically significant at p < 0.050

Both collagen deposit and type I collagen formation were higher in the T-UC MSCs group than those in the CPA group at 2 weeks. At 2 weeks, the CPA group showed low collagen formation which consists of low-density type I collagen, and it remained until 4 weeks. However, the T-UC MSCs group showed higher collagen formation which consists of high-density type I collagen than that in the CPA group, and the type I collagen in T-UC MSCs group became more dense at 4 weeks. Moreover, there was no significant difference between C-UC MSCs and T-UC MSCs groups at 2 and 4 weeks (Fig. 4b, c).

In terms of GAG-rich area, the area was significantly smaller in the T-UC MSCs (42.49 ± 36.59 N) than in the CPA group (358.05 ± 187.26 N) at 2 weeks (p = 0.001), and there was no significant difference between C-UC MSCs (40.21 ± 13.99 mm2) and T-UC MSCs. After 4 weeks, the GAG-rich area was less in the T-UC MSC groups (36.59 ± 44.21 mm2) compared with that of the CPA group (690.99 ± 125.45 mm2) (p = 0.024). There was no significant difference between C-UC MSCs (30.72 ± 21.79 mm2) and T-UC MSCs (Fig. 5a, b).

Fig. 5.

Fig. 5

Open in a new tab

Quantification of GAG-rich area in the regenerated tendons at 2 and 4 weeks after injection with saline, CPA, and C- and T-UC MSCs. a Alcian blue staining of the tendon (magnification; × 200). b GAG-rich area of the tendon. Bar charts represent mean ± standard deviation; statistically significant at p < 0.050

Biomechanical evaluation

The value of ultimate failure load was significantly higher in the T-UC MSCs (16.69 ± 2.20 N) than in the CPA group (10.79 ± 1.18 N) at 2 weeks (p < 0.001). After 4 weeks, the value was also enhanced in the T-UC MSCs (22.33 ± 1.75 N) compared with the control groups (17.59 ± 4.12 N) (p = 0.043). There was no significant difference between C-UC MSCs at 2 weeks (18.40 ± 2.67 N) and at 4 weeks (23.40 ± 2.06 N) and T-UC MSCs at both 2 and 4 weeks (Fig. 6b).

Fig. 6.

Fig. 6

Open in a new tab

Biomechanical procedure and quantification of the properties of regenerated tendons at 2 and 4 weeks after injection with saline, CPA, and C- and T-UC MSCs. a A harvested supraspinatus tendon attached to the proximal humerus, and the procedure outline the biomechanical experiment. b Ultimate failure load. c Stiffness. d Ultimate stress. e Cross-sectional area of the supraspinatus tendon at defect site. Bar charts represent mean ± standard deviation; statistically significant at p < 0.050

The value of stiffness was improved significantly in the T-UC MSCs group (6.27 ± 0.95 N/mm) compared with that of the CPA group (4.97 ± 0.61 N/mm) at 2 weeks (p = 0.008). There was no significant difference between C-UC MSCs (7.30 ± 0.74 N/mm) and T-UC MSCs groups. After 4 weeks, stiffness was higher in T-UC MSCs (8.08 ± 0.81 N/mm) than that in CPA group (7.04 ± 1.04 N/mm), but there was no significant difference between groups (Fig. 6c).

In ultimate stress, there was no significant difference between T-UC MSCs and CPA groups at 2 weeks due to the increased cross-sectional area of tendon in T-UC MSCs. However, after 4 weeks, ultimate stress was higher in T-UC MSCs (7.03 ± 0.71 MPa) than that in CPA group (5.85 ± 2.16 MPa) although there was no significant difference (Fig. 6d, e).

UC MSCs trafficking

At 2 weeks, the mean number of PKH26-labeled cells per area was reduced by 21.40% in T-UC MSCs compared to that at 0 day (p < 0.000), and there was no significant difference between C-UC MSCs (194.15 ± 24.28 cells/mm2) and T-UC MSCs (168.83 ± 24.11 cells/mm2). After 4 weeks, the mean number of cells significantly decreased 8.77% in T-UC MSCs compared to that at 0 day, and there was no significant difference between C-UC MSCs (64.07 ± 22.43 cells/mm2) and T-UC MSCs (69.17 ± 27.07 cells/mm2) (p < 0.000) (Fig. 7).

Fig. 7.

Fig. 7

Open in a new tab

Cell trafficking for UC MSCs within the tendon and quantification of the UC MSCs on the day after injection and at 2 and 4 weeks after injection. a: PKH26-labeled UC MSCs with DAPI within the tendon (magnification; × 400). b The number of the UC MSCs per area (mm2). Bar charts represent mean ± standard deviation; statistically significant at p < 0.050

Discussion

The most important findings of this study include (1) The T-UC MSCs exhibited fibroblast-like morphology and above 97% viability and stable proliferation comparable to that of the C-UC MSCs at passage 10. (2) In a rat model of FTD, macroscopic appearance improved in T-UC MSCs compared with the control (CPA) group at both 2 and 4 weeks in terms of inflammation, defect size, neighboring tendon, swelling/redness, and the connecting surrounding tissue and slidability, and there was no significant difference between T- and C-UC MSCs groups. (3) Histologically, compared to the control group, the nuclear aspect ratio, orientation angle of fibroblasts, collagen organization, and fiber coherence were improved by 33.33%, 42.75%, 1.86-fold, and 1.99-fold and GAG-rich area decreased by improved by 88.13% at 2 weeks and 94.70% at 4 weeks. All improved values of T-UC MSCs group were comparable to those of C-UC MSCs group. (4) The ultimate failure load was 1.55- and 1.25-fold higher in the T-UC MSCs than in the control group at both 2 and 4 weeks, respectively, and there was no significant difference between C- and T-UC MSCs. Taken together, these results showed that T-UC MSCs showed comparable survival and proliferation to those of C-UC MSCs, and treatment with T-UC MSCs improved the regeneration of rotator cuff tendon in terms of macroscopic, histological, and biomechanical properties, which were comparable to those of treatment with C-UC MSCs.

MSCs are known to be effective in preclinical immunomodulatory and regenerative studies; however, the use of MSCs in clinical practice is a concern in that freshly thawed MSCs may degrade during the thawing procedure. Clinical trials generally use freshly thawed cells that are readily retrieved from cryostorage whereas preclinical experiments use fresh cells [34]. Thus, the difference in effectiveness between freshly thawed cells and fresh cells must be demonstrated. Although thawing afresh minimally affected cell growth, differentiation, and general phenotypes, viability and bioactivity were affected [16]. Some studies reported that continuously cultured cells exhibit ~ 100% viability after harvest afresh, whereas freshly thawed cells have only ~ 70% viability [18] and in worst cases, ~ 50% of viability [35]. Conversely, T-UC MSCs, in this study, showed above 97% viability of cells with comparable morphology and proliferation compared with the C-UC MSCs even after fresh thawing procedure. Cell viability depends on the thawing method, duration of cold storage, and reagents used [36]. Relatively short storage periods [37] and optimal concentration of DMSO (10%) are crucial factors contributing to high cell viability in cryopreserved conditions [35, 37–39]. Other conditions not mentioned here may have an impact on the high cell viability in this study. In conclusion, our results suggest successful cryopreservation of UC MSCs to maintain cell conditions similar to continuously cultured MSCs after fresh thawing procedure [37].

Recent studies reported the efficacy of cryopreserved MSCs with inconsistent results in animal models. Moll et al. demonstrated that freshly thawed MSCs showed reduced viability and increased apoptosis and were associated with negative immunomodulatory effects and blood regulation resulting in faster complement-mediated elimination after blood exposure [16]. However, Cruz et al. reported that freshly thawed human BM MSCs could regulate allergic airway inflammation in an immunocompetent mouse model, and no significant differences were found between cultured MSCs and freshly thawed MSCs [18]. In fact, the freshly thawed MSCs numbered 1.3 × 106 cells, whereas the cultured MSCs were only 1 × 106 cells considering dead cells because the freshly thawed MSCs showed a viability of 70% [18]. These results suggested that an adequate number of living cells are important for healing capacity, and thus, the high cell viability of freshly thawed MSCs is also a crucial factor determining the efficacy comparable to the fresh cultured MSCs. In this study, we used the same number of MSCs in both C- and T-UC MSCs for animal experiments and found comparable potential for tendon regeneration using T-UC MSCs and C-UC MSCs. This study demonstrated that the high viability of cells and adequate cell numbers positively contributed to recovery from tendon injury.

European studies of ex vivo-expanded cells generally use passages 1–4, whereas passages beyond 5 were commonly used in company-sponsored phase three trials [34]. In patients with acute graft-versus-host disease, 75% of early-passage BM MSCs (passage 1–2) survived after 1 year and only 21% of later passage MSCs (passages 3–4) survived [40], suggesting the reduced therapeutic value and potency of high passage MSCs [16]. By contrast, we found the efficacy of UC MSCs even though passage 10 was used (although not compared by passage) because UC MSCs remain immature even after several passages, and no genetic changes were detected following long-term expansion [41]. Further, using our isolation and culture method to manipulate UC MSCs, no difference was found in CPDL, proliferation, pluripotent stem cell markers, or differentiation among UCMSCs with passages 2, 3, 7, and 9, and the stemness persisted even with passaging and senescence. Telomeric results showed no difference according to the passage [19]. Furthermore, Zhuang et al. reported that human UC MSCs after passage 15 exhibited stronger immunosuppressive activity than those after early passage (passage 3), suggesting that at later passages, human UC MSCs represent a good therapeutic option for patients with graft versus host disease and other immune diseases [42]. Hence, it is suggested that MSCs at an early passage might not necessarily be better, and T-UC MSCs at passage 10 exhibit enough positive effect on tendon regeneration suggesting the possibility of using UC MSCs as “off-the-shelf” treatments for patients clinically.

Although there were histological and biomechanical improvements until 4 weeks after UC MSCs injection, most of the injected UC MSCs faded away at the injured tendon over time. Recently, several studies have shown that the healing effect of MSCs comes from the paracrine effect, which secrete cytokines and growth factors to recruit, proliferate, and differentiate tissue-specific progenitor cells to synthesis-specific matrix [43]. Moreover, MSCs have the ability to modulate local inflammatory environment by regulating inflammatory cell function by inducing macrophage recruitment and polarization to alternatively activated macrophage suppressing inflammation and the inflammatory-related cells [44, 45]. Thus, the injected UC MSCs disappeared over time, but the local environment influenced by UC MSCs has a positive effect on the regeneration of the structure of the injured tendon. However, more study is needed to explain the healing effects of UC MSC on tendon regeneration.

There are several limitations in this study. First, we did not perform gene expression and protein synthesis evaluation, and it is difficult to prove the mechanism of the healing effects of UC MSCs. Second, we only investigated tendon regeneration at 2 and 4 weeks after injecting UC MSCs, which was a brief period to adequately determine the efficacy of T-UC MSCs. Thus, a long-term follow-up study is needed to confirm the sustained efficacy of treatment with C- and T-UC MSCs.

Conclusions

The morphology, viability, and proliferation of T-UC MSCs were comparable to those of C-UC MSCs. Treatment with T-UC MSCs could induce tendon regeneration of FTD at the macroscopic, histological, and biomechanical levels comparable to treatment with C-UC MSCs.

Supplementary information

13287_2020_1906_MOESM1_ESM.docx (393KB, docx)

Additional file 1 Procedure of experiments.

13287_2020_1906_MOESM2_ESM.docx (60KB, docx)

Additional file 2 Modified macroscopic evaluation system.

Additional file 3. (63.5KB, docx)
Additional file 4 UC MSCs Trafficking. (66.8KB, docx)

Acknowledgements

Not applicable.

Abbreviations

MSCs

Mesenchymal stem cells

FTD

Full-thickness tendon defect

CPA

Cryopreserved agent

C-UC MSCs

Cultured umbilical cord-derived MSCs

T-UC MSCs

Freshly thawed umbilical cord-derived MSCs

BM MSCs

Bone marrow-derived MSCs

AD MSCs

Adipose tissue-derived MSCs

UC MSCs

Umbilical cord-derived MSCs

WST

Water-soluble tetrazolium salt

OD

Optical density

CPDL

Cumulative population-doubling level

PDT

Population-doubling time

SST

Supraspinatus tendon tissue

EDTA

Ethylendiaminetetracetic acid

H&E

Hematoxylin and eosin

ROI

Regions of interest

PSR

Picrosirius red

Saf-O

Safranin-O/fast green

GAG

Glycosaminoglycan

ANOVA

One-way analysis of variance

Authors’ contributions

J.H.Y. contributed to the conception and the experiment design; performed animal experiments, acquisition and analysis, and interpretation of data; and wrote the manuscript. J.K.P. performed cell experiments, acquisition and analysis, and interpretation of data and wrote the manuscript. I.J.K. performed animal experiments. G.Y.S. performed animal experiments. T.S.B. contributed to the biomechanical experiments and manuscript editing. C.H.J. contributed to the study design and manuscript editing. All authors have read and approved the final submitted manuscript.

Funding

This study was supported by a grant (NRF-2015M3A9E6028412) of the Bio & Medical Technology Development Program and a grant (NRF-2017R1A2B2010995) awarded by the Basic Science Research Program of the National Research Foundation of Korea.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Human umbilical cords were harvested from patients with written consent under approval by the Institutional Review Board of Seoul Metropolitan Government Seoul National University Boramae Medical Center (IRB No. 16-2015-115). Animal experiments were conducted in accordance with the protocol approved by the Institutional Animal Care and Use Committee of Seoul Metropolitan Government Seoul National University Boramae Medical Center (IACUC_2020_0004).

Consent for publication

Not applicable.

Competing interests

C.H.J. owns shares of AcesoStem Biostrategies Inc. The other authors indicated no potential conflicts of interest.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary information accompanies this paper at 10.1186/s13287-020-01906-1.

References

  • 1.Abat F, Alfredson H, Cucchiarini M, Madry H, Marmotti A, Mouton C, et al. Current trends in tendinopathy: consensus of the ESSKA basic science committee. Part I: biology, biomechanics, anatomy and an exercise-based approach. J Exp Orthop. 2017;4(1):1–18. doi: 10.1186/s40634-017-0092-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Hermans J, Luime JJ, Meuffels DE, Reijman M, Simel DL, Bierma-Zeinstra SMA. Does this patient with shoulder pain have rotator cuff disease? The rational clinical examination systematic review. JAMA. 2013;310(8):837–847. doi: 10.1001/jama.2013.276187. [DOI] [PubMed] [Google Scholar]
  • 3.Narayanan G, Nair LS, Laurencin CT. Regenerative engineering of the rotator cuff of the shoulder. Acs Biomater Sci Eng. 2018;4(3):751–786. doi: 10.1021/acsbiomaterials.7b00631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Van der Windt D, Koes BW, Boeke A, Devillé W, De Jong BA, Bouter LM. Shoulder disorders in general practice: prognostic indicators of outcome. Br J Gen Pract. 1996;46(410):519–523. [PMC free article] [PubMed] [Google Scholar]
  • 5.Schneider M, Angele P, Jarvinen TAH, Docheva D. Rescue plan for Achilles: therapeutics steering the fate and functions of stem cells in tendon wound healing. Adv Drug Deliv Rev. 2018;129:352–375. doi: 10.1016/j.addr.2017.12.016. [DOI] [PubMed] [Google Scholar]
  • 6.De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A, Pascual CY, Aller MA, Arias J, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012;12(5):574–591. doi: 10.2174/156652412800619950. [DOI] [PubMed] [Google Scholar]
  • 7.Degen RM, Carbone A, Carballo C, Zong JC, Chen T, Lebaschi A, et al. The effect of purified human bone marrow-derived mesenchymal stem cells on rotator cuff tendon healing in an athymic rat. Arthroscopy. 2016;32(12):2435–2443. doi: 10.1016/j.arthro.2016.04.019. [DOI] [PubMed] [Google Scholar]
  • 8.Chen HS, Su YT, Chan TM, Su YJ, Syu WS, Harn HJ, et al. Human adipose-derived stem cells accelerate the restoration of tensile strength of tendon and alleviate the progression of rotator cuff injury in a rat model. Cell Transplant. 2015;24(3):509–520. doi: 10.3727/096368915X686968. [DOI] [PubMed] [Google Scholar]
  • 9.Uthoff H, Spenner A, Reckelkamm W, Ahrens B, Wolk G, Hackler R, et al. Critical role of preconceptional immunization for protective and nonpathological specific immunity in murine neonates. J Immunol. 2003;171(7):3485–3492. doi: 10.4049/jimmunol.171.7.3485. [DOI] [PubMed] [Google Scholar]
  • 10.Troyer DL, Weiss ML. Concise review: Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells. 2008;26(3):591–599. doi: 10.1634/stemcells.2007-0439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hsieh CF, Alberton P, Loffredo-Verde E, Volkmer E, Pietschmann M, Muller P, et al. Scaffold-free Scleraxis-programmed tendon progenitors aid in significantly enhanced repair of full-size Achilles tendon rupture. Nanomedicine (Lond) 2016;11(9):1153–1167. doi: 10.2217/nnm.16.34. [DOI] [PubMed] [Google Scholar]
  • 12.Beeravolu N, Khan I, McKee C, Dinda S, Thibodeau B, Wilson G, et al. Isolation and comparative analysis of potential stem/progenitor cells from different regions of human umbilical cord. Stem Cell Res. 2016;16(3):696–711. doi: 10.1016/j.scr.2016.04.010. [DOI] [PubMed] [Google Scholar]
  • 13.Wu KH, Zhou B, Lu SH, Feng B, Yang SG, Du WT, et al. In vitro and in vivo differentiation of human umbilical cord derived stem cells into endothelial cells. J Cell Biochem. 2007;100(3):608–616. doi: 10.1002/jcb.21078. [DOI] [PubMed] [Google Scholar]
  • 14.Li MR, Luan FX, Zhao YL, Hao HJ, Liu JJ, Dong L, et al. Mesenchymal stem cell-conditioned medium accelerates wound healing with fewer scars. Int Wound J. 2017;14(1):64–73. doi: 10.1111/iwj.12551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yong KW, Wan Safwani WKZ, Xu F, Wan Abas WAB, Choi JR, Pingguan-Murphy B. Cryopreservation of human mesenchymal stem cells for clinical applications: current methods and challenges. Biopreservation Biobanking. 2015;13(4):231–239. doi: 10.1089/bio.2014.0104. [DOI] [PubMed] [Google Scholar]
  • 16.Moll G, Geissler S, Catar R, Ignatowicz L, Hoogduijn MJ, Strunk D, et al. Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy? Adv Exp Med Biol. 2016;951:77–98. doi: 10.1007/978-3-319-45457-3_7. [DOI] [PubMed] [Google Scholar]
  • 17.Chinnadurai R, Garcia MA, Sakurai Y, Lam WA, Kirk AD, Galipeau J, et al. Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. Stem Cell Rep. 2014;3(1):60–72. doi: 10.1016/j.stemcr.2014.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner D, McKenna DH, et al. Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice. Stem Cell Transl Med. 2015;4(6):615–624. doi: 10.5966/sctm.2014-0268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Jo CH, Kim OS, Park EY, Kim BJ, Lee JH, Kang SB, et al. Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. Cell Tissue Res. 2008;334(3):423–433. doi: 10.1007/s00441-008-0696-3. [DOI] [PubMed] [Google Scholar]
  • 20.Vidal MA, Kilroy GE, Johnson JR, Lopez MJ, Moore RM, Gimble JM. Cell growth characteristics and differentiation frequency of adherent equine bone marrow-derived mesenchymal stromal cells: adipogenic and osteogenic capacity. Vet Surg. 2006;35(7):601–610. doi: 10.1111/j.1532-950X.2006.00197.x. [DOI] [PubMed] [Google Scholar]
  • 21.Carpenter JE, Thomopoulos S, Flanagan CL, DeBano CM, Soslowsky LJ. Rotator cuff defect healing: a biomechanical and histologic analysis in an animal model. J Shoulder Elb Surg. 1998;7(6):599–605. doi: 10.1016/s1058-2746(98)90007-6. [DOI] [PubMed] [Google Scholar]
  • 22.Stoll C, John T, Conrad C, Lohan A, Hondke S, Ertel W, et al. Healing parameters in a rabbit partial tendon defect following tenocyte/biomaterial implantation. Biomaterials. 2011;32(21):4806–4815. doi: 10.1016/j.biomaterials.2011.03.026. [DOI] [PubMed] [Google Scholar]
  • 23.Jo CH, Shin WH, Park JW, Shin JS, Kim JE. Degree of tendon degeneration and stage of rotator cuff disease. Knee Surg Sport Tr A. 2017;25(7):2100–2108. doi: 10.1007/s00167-016-4376-7. [DOI] [PubMed] [Google Scholar]
  • 24.Chen L, Liu JP, Tang KL, Wang Q, Wang GD, Cai XH, et al. Tendon derived stem cells promote platelet-rich plasma healing in collagenase-induced rat achilles tendinopathy. Cell Physiol Biochem. 2014;34(6):2153–2168. doi: 10.1159/000369659. [DOI] [PubMed] [Google Scholar]
  • 25.Fernandez-Sarmiento JA, Dominguez JM, Granados MM, Morgaz J, Navarrete R, Carrillo JM, et al. Histological study of the influence of plasma rich in growth factors (PRGF) on the healing of divided Achilles tendons in sheep. J Bone Joint Surg Am. 2013;95(3):246–255. doi: 10.2106/JBJS.K.01659. [DOI] [PubMed] [Google Scholar]
  • 26.Kraus TM, Imhoff FB, Reinert J, Wexel G, Wolf A, Hirsch D, et al. Stem cells and bFGF in tendon healing: effects of lentiviral gene transfer and long-term follow-up in a rat Achilles tendon defect model. Bmc Musculoskel Dis. 2016;17(148):1–7. doi: 10.1186/s12891-016-0999-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zhao S, Zhao JW, Dong SK, Huangfu XQ, Bin L, Yang HL, et al. Biological augmentation of rotator cuff repair using bFGF-loaded electrospun poly (lactide-co-glycolide) fibrous membranes. Int J Nanomedicine. 2014;9:2373–2385. doi: 10.2147/IJN.S59536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yea J-H, Bae TS, Kim BJ, Cho YW, Jo CH. Regeneration of the rotator cuff tendon-to-bone interface using umbilical cord-derived mesenchymal stem cells and gradient extracellular matrix scaffolds from adipose tissue in a rat model. Acta Biomaterialia. 2020;114:104–16. [DOI] [PubMed]
  • 29.Galatz LM, Charlton N, Das R, Kim HM, Havlioglu N, Thomopoulos S. Complete removal of load is detrimental to rotator cuff healing. J Shoulder Elb Surg. 2009;18(5):669–675. doi: 10.1016/j.jse.2009.02.016. [DOI] [PubMed] [Google Scholar]
  • 30.Beck J, Evans D, Tonino PM, Yong S, Callaci JJ. The biomechanical and histologic effects of platelet-rich plasma on rat rotator cuff repairs. Am J Sports Med. 2012;40(9):2037–2044. doi: 10.1177/0363546512453300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Galatz L, Silva M, Rothermich S, Zaegel M, Havlioglu N, Thomopoulos S. Nicotine delays tendon-to-bone healing in a rat shoulder model. JBJS. 2006;88(9):2027–2034. doi: 10.2106/JBJS.E.00899. [DOI] [PubMed] [Google Scholar]
  • 32.Li SY, Gao Y, Tokuyama T, Yamamoto J, Yokota N, Yamamoto S, et al. Genetically engineered neural stem cells migrate and suppress glioma cell growth at distant intracranial sites. Cancer Lett. 2007;251(2):220–227. doi: 10.1016/j.canlet.2006.11.024. [DOI] [PubMed] [Google Scholar]
  • 33.Kang ES, Ha KY, Kim YH. Fate of transplanted bone marrow derived mesenchymal stem cells following spinal cord injury in rats by transplantation routes. J Korean Med Sci. 2012;27(6):586–593. doi: 10.3346/jkms.2012.27.6.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Galipeau J. The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15(1):2–8. doi: 10.1016/j.jcyt.2012.10.002. [DOI] [PubMed] [Google Scholar]
  • 35.François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. Cytotherapy. 2012;14(2):147–152. doi: 10.3109/14653249.2011.623691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Antebi B, Asher AM, Rodriguez LA, Moore RK, Mohammadipoor A, Cancio LC. Cryopreserved mesenchymal stem cells regain functional potency following a 24-h acclimation period. J Transl Med. 2019;17:297–310. [DOI] [PMC free article] [PubMed]
  • 37.Ginis I, Grinblat B, Shirvan MH. Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium. Tissue Eng Part C-Me. 2012;18(6):453–463. doi: 10.1089/ten.TEC.2011.0395. [DOI] [PubMed] [Google Scholar]
  • 38.Hu S, Zhu QC, Han C, Zhang XG, Song BY, Xie DQ, et al. Effects of different cryoprotectants on the cryopreservation of cattle testicular tissue. Arch Tierzucht. 2015;58;433–9.
  • 39.Zhang XG, Li H, Hu JH. Effects of various cryoprotectants on the quality of frozen-thawed immature bovine (Qinchuan cattle) calf testicular tissue. Andrologia. 2017;49(9);e12743. [DOI] [PubMed]
  • 40.von Bahr L, Sundberg B, Lönnies L, Sander B, Karbach H, Hägglund H, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood and Marrow Transplant. 2012;18(4):557–564. doi: 10.1016/j.bbmt.2011.07.023. [DOI] [PubMed] [Google Scholar]
  • 41.Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp DÖ, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells. 2007;25(2):319–331. doi: 10.1634/stemcells.2006-0286. [DOI] [PubMed] [Google Scholar]
  • 42.Zhuang Y, Li D, Fu JQ, Shi Q, Lu YY, Ju XL. Comparison of biological properties of umbilical cord-derived mesenchymal stem cells from early and late passages: Immunomodulatory ability is enhanced in aged cells. Mol Med Rep. 2015;11(1):166–174. doi: 10.3892/mmr.2014.2755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Zhang B, Luo Q, Halim A, Ju Y, Morita Y, Song G. Directed differentiation and paracrine mechanisms of mesenchymal stem cells: potential implications for tendon repair and regeneration. Curr Stem Cell Res Ther. 2017;12(6):447–454. doi: 10.2174/1574888X12666170502102423. [DOI] [PubMed] [Google Scholar]
  • 44.El Omar R, Beroud J, Stoltz JF, Menu P, Velot E, Decot V. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Eng Part B Rev. 2014;20(5):523–544. doi: 10.1089/ten.TEB.2013.0664. [DOI] [PubMed] [Google Scholar]
  • 45.Bianco ST, Moser HL, Galatz LM, Huang AH. Biologics and stem cell-based therapies for rotator cuff repair. Ann N Y Acad Sci. 2018;1442(1):35–47. doi: 10.1111/nyas.13918. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

13287_2020_1906_MOESM1_ESM.docx (393KB, docx)

Additional file 1 Procedure of experiments.

13287_2020_1906_MOESM2_ESM.docx (60KB, docx)

Additional file 2 Modified macroscopic evaluation system.

Additional file 3. (63.5KB, docx)
Additional file 4 UC MSCs Trafficking. (66.8KB, docx)

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Articles from Stem Cell Research & Therapy are provided here courtesy of BMC

RESOURCES